Abstract:
Objective To explore the application value of 68Ga-fibroblast activation protein inhibitors (FAPI) PET radiomics models in the preoperative assessment of the degree of pathological differentiation of hepatocellular carcinoma (HCC).
Methods A retrospective cohort study analysis was performed with 90 HCC patients (80 males, 10 females;aged (59.4±9.9) years) who underwent 68Ga-FAPI PET from June 2021 to June 2023, the Chongqing University Cancer Hospital. Patients were randomly divided into a training set (64 cases) and a test set (26 cases) by simple random sampling. Feature extraction was performed after drawing the volume of interest (VOI) of the lesion on 68Ga-FAPI PET images. Four classifiers (logistic regression (LR), naive Bayes (NB), K-nearest neighbors (KNN), randorn forest (RF)) were employed for machine learning to construct PET radiomics models, which were evaluated using the receiver operating characteristic (ROC) curves. Area under the curve (AUC) and other performance parameters were then calculated. Intergroup differences between the training and test sets were compared using independent-sample t-test, Wilcoxon rank-sum test, and Chi-square test.
Results No significant differences were observed in general clinical data and pathological differentiation outcomes between the training and test sets (χ2=0.002, 0.433, t=−0.138–0.067, Z=1.019, all P>0.05). In the training set, the LR model achieved the highest AUC (0.882 (95%CI: 0.788–0.796)) and sensitivity (0.957), and the KNN model demonstrated the highest specificity (0.938). In the test set, the LR model exhibited the highest AUC (0.878 (95%CI: 0.751–1.000), and the LR and RF models achieved the highest sensitivity (0.933). The NB and KNN models showed the highest specificity (0.833).
Conclusions The radiomics model based on 68Ga-FAPI PET images was established via machine learning. The model holds significant value for preoperative prediction of HCC pathological differentiation degree and may facilitate personalized preoperative assessment for patients with HCC.